Services | Dalriada

THREE PILLARS

OF TURN-KEY MODEL

1. Internal R&D

2. Program Management

3. Business and IP Support

TURN-KEY INTERNAL R&D

Expert Drug Discovery
R&D Teams Under

One Roof

Design and Deploy
Highly Efficient
Screening Cascades

allows reaching go/no-go
decisions fastest in the industry

Retain Execution
of First-Line Assays
In-House

Partner on fully
integrated programs
or select program needs

Guaranteed R&D execution
at top industry standard

Hit generation –

lead validation

Compound design - validation of the mode of action

Design of screening
cascade and assay selection

Benchmarking against mechanism –
and clinically-relevant compounds

Oversight of experimental
design for outsourced studies

Ideally suited for innovative therapeutic programs allowing full customization of existing and development of new assays

Highly experienced scientific team specifically tailored for each project – all R&D performed in Canada

Direct line of communication with project lead scientists, convenient EST time zone

Real-time access to project results on the cloud,

E-lab book and compound registration modules

The expertise of our internal scientific team spans all major areas of small molecule drug discovery and preclinical development to enable the most innovative of projects and rapidly develop the asset

See all internal

R&D capabilities

COVALENT INHIBITOR

DEVELOPMENT

From early screens for stability against biological nucleophiles to the design of washout experiments, covalent inhibitor development necessitates a non-standard set of screening conditions and a unique set of studies on the critical path to development that are not accounted for by the majority of CROs and often mislead the drug discovery project.

Dalriada offers most comprehensive and expert support in this field, including
a proprietary screening cascade.

Learn more

CELL BIOLOGY

We offer a wide range of cellular and molecular biology assays to characterize phenotypic SAR and the molecular pathways affected by the drug candidates.

Assays

Cell-based functional screens
Cell viability and proliferation
>70 cancer and normal cell
lines in-house
Primary cells
Custom phenotypic assays
Immuno-assays (Western,
ELISA)
RT-PCR
Radioligand-based assays
(e.g. GPCR)

Instrumentation

Flow Cytometry
Microplate readers
HT Fluorescence
Microscopy
Confocal Microscopy
Fluorescence-coupled thermal cyclers

Supporting projects from early discovery
to late-stage lead optimization

MEDICINAL CHEMISTRY

Medicinal Chemistry

Target Expertise

Rational drug design
Computational modeling
In-silico screening
DFT calculations
Hit ID
Hit-to-Lead SAR
Lead optimization SAR
StarDrop™ QSAR analysis

Kinase inhibitors

Enzyme inhibitors

Targeted covalent inhibitors

Protein-protein interaction inhibitors

GPCR

IN VITRO ASSAY

We offer fully customizable assay development to enable the SAR efforts of your drug discovery projects and provide detailed kinetic and thermodynamic characterization for the lead compounds

Radioligand
displacement assays
SPR (automated,
microplate format)
ITC (automated,
microplate format)
NMR binding studies
LC-MS/MS
Fluorescence-coupled
assays

Fluorescence polarization
Thermal shift assays
Luminex assays
Custom assay development
Custom protein expression
Protein mutagenesis
and labeling
Protein-ligand co-crystallization

IN VITRO ADME

We conduct all essential in vitro ADME profiling to accelerate SAR and advance the asset

Microsomal & hepatocyte stability
GSH stability
Plasma and/or whole
blood stability
Permeability (Caco-2,
PAMPA, MDCK)

CYP450 inhibition/
induction
Metabolite ID
Proprietary Covalent
Cascade

Analytical

NMR ( H, C, F)
Analytical HPLC
LC-MS/MS
Elemental Analysis
IR

Synthesis

Libraries (mg)
Scale-up (g)
Peptide synthesis
Microwave-assisted synthesis
Automated chromatography
Preparative HPLC
Online inventory, barcoded

Synthesis support:

Synthesis of small
molecule libraries (mg)
Scale-up of
lead compound (s)

PK, Tox, Preclinical Studies

Efficacy Studies:

Study design
Formulation development
Primary patient samples
Primary and refractory tumour samples
Expertise in cancer models
(including heme and brain)

In Vivo:

Formulation optimization
Pharmacokinetics (ip, po, iv)
Tolerability/MTD

PK/PD
Efficacy
Bio-distribution studies

INSTRUMENTATION

Liquid Scintillation Counter

Biotage Isolera Flash Chromatography

MagPix

Microcal
PEAQ-ITC

CytoFlexS FACs

Biotage Peptide Synthesizer

Analytical and preparative
HPLC units

400 MHz NMR

Microplate Readers
and Fluorescence Microscopes

Biacore T200 SPR

Biotage
Microwave Initiator

Variety of LC/MS and LC/MS/MS

END-TO-END

PROGRAM MANAGEMENT

The lean approach and (semi)-virtual set-up of innovative biotechs requires sourcing of diverse expertise and management of multiple outsourced contracts.

Dalriada lightens this operational load by centralizing the project management under one umbrella.

Identify and Coordinate
All Outsourcing Needs

Manage Data
Workflow

and Storage

Source Exclusive Scientific Capabilities

CROs –
Collaborators –
IP – Legal

Preparation and management of data rooms for due diligence

Through existing partnerships and new engagements with world-leading academic
investigators fundamental science – preclinical – clinical

Identify and Engage Key Scientific and

Business Expertise
for Your Project

KOLs – consultants.
Industry – academia

BUSINESS AND
IP SUPPORT

Dalriada keeps the business goals of the program as a top priority and supports lean (semi) virtual organizations to enable the most cost-effective R&D program and build
the highest value for the asset.

We follow an “R&D-to-milestone” approach, where the R&D is designed to reach milestones and position the assets for a successful exit.

Each asset, and type of exit (investment/partnership/IND candidate), requires a unique strategy and R&D package. We assist with and facilitate every aspect of this process.

Scientific Team

trained by a top US Law Firm

We act as a liaison between both

your patent attorney and scientific team to develop and effectively communicate the R&D exemplification required to enable the patent claims and provide the strongest IP protection to your asset(s).

Industry positioning
and asset development
roadmap

To optimize the design of the R&D program early-on and powerfully position the asset and program in the field

Integrated
IP support

We directly assist with IP strategy development in the NCE space that is most suitable for your particular project, competition level in the field, budget, and asset exit goals

Market analysis

Indications selection
Analysis of competitors’ pipelines
Shaping target product profile (TPP)
Engagement of appropriate KOLs
from industry and academia
Program positioning for potential investors and partners
Selection of the most relevant benchmark compounds (clinical and mechanism-specific benchmarks; SOC; competitor’s leads)

Prior art landscaping
Defining required exemplification
Preparing application drafts
Patentability searches
Identification of white space
Selection of a patent attorney
Monitoring of competitors’ activity
Informal freedom to operate
Top patent firm partners